Gibson Dunn, Cooley Guide Merck's $9.2B Cidara Buy

By Al Barbarino · November 14, 2025, 12:19 PM EST

Gibson Dunn & Crutcher LLP-advised Merck on Friday said it will broaden its respiratory portfolio with a $9.2 billion deal to buy Cooley LLP-led Cidara Therapeutics, betting that an investigational antiviral could...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login